In a report issued on June 9, Brian Abrahams from RBC Capital maintained a Buy rating on NeuBase Therapeutics (NBSE), with a price target of $16.00. The company’s shares closed last Thursday at $5.30, close to its 52-week low of $4.51.
According to TipRanks.com, Abrahams is a 4-star analyst with an average return of 7.0% and a 48.5% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals, Intra-Cellular Therapies, and Karyopharm Therapeutics.
NeuBase Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $16.00, a 201.3% upside from current levels. In a report issued on June 1, H.C. Wainwright also reiterated a Buy rating on the stock with a $15.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $12.89 and a one-year low of $4.51. Currently, NeuBase Therapeutics has an average volume of 339.8K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
NeuBase Therapeutics, Inc. engages in the development of drugs for patients with genetic neurological disorder. Its pipelines include Huntington’s Disease, NT0100 Program – PATrOL Enabled gamma-PNA for Huntington’s Disease, and NT0200 Program- PATrOL Enabled gamma-PNA for Myotonic Dystophy. The company was founded by Dietrich A. Stephan on August 28, 2018 and is headquartered in Pittsburgh, PA.
